Evidence map›Paper›PMID 40644429›Full record

SynthesisAnnals of medicine2025

Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.

Xiaobin Gu, Yonggang Shi

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaobin GuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yonggang ShiDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcopenia is widely explored for its significance for predicting nasopharyngeal carcinoma (NPC) prognosis, yet current results are inconsistent. Consequently, this meta-analysis focused on investigating its precise role in predicting NPC prognosis.

methodsWe systemically retrieved studies in PubMed, Web of Science, Embase and Cochrane Library from inception to 17 March 2025. Sarcopenia was analysed for its role in predicting overall survival (OS) and progression-free survival (PFS) in NPC through determining combined hazard ratios (HRs) and 95% confidence intervals (CIs). Thereafter, associations of sarcopenia with NPC clinicopathological factors were estimated through aggregating odds ratios (ORs) with 95%CIs.

resultsThere were eight studies with 5458 cases enrolled in this study. Based on the aggregated findings, sarcopenia was remarkably related to unfavourable OS (HR = 1.88, 95% CI = 1.47-2.40,

conclusionsThis meta-analysis demonstrated that sarcopenia was a significant prognostic marker for poor OS and PFS in patients with NPC. Moreover, sarcopenia was also significantly associated with higher T stage of NPC.

Indexed as

Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsSarcopeniaFemaleHumansMaleNeoplasm StagingPrognosisProgression-Free Survivalbiomarkerevidence-based medicinemeta-analysisnasopharyngeal carcinomaSarcopenia

Identifiers

PMID40644429
PMCPMC12258165

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.